Shanghai Institute of Materia, Chinese Academy of Sciences, Shanghai, China.
Br J Clin Pharmacol. 2012 Feb;73(2):268-84. doi: 10.1111/j.1365-2125.2011.04076.x.
The most common causes of variability in drug response include differences in drug metabolism, especially when the hepatic cytochrome P450 (CYP) enzymes are involved. The current study was conducted to assess the differences in CYP activities in human liver microsomes (HLM) of Chinese or Caucasian origin.
The metabolic capabilities of CYP enzymes in 30 Chinese liver microsomal samples were compared with those of 30 Caucasian samples utilizing enzyme kinetics. Phenacetin O-deethylation, coumarin 7-hydroxylation, bupropion hydroxylation, amodiaquine N-desethylation, diclofenac 4'-hydroxylation (S)-mephenytoin 4'-hydroxylation, dextromethorphan O-demethylation, chlorzoxazone 6-hydroxylation and midazolam 1'-hydroxylation/testosterone 6β-hydroxylation were used as probes for activities of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A, respectively. Mann-Whitney U test was used to assess the differences.
The samples of the two ethnic groups were not significantly different in cytochrome-b(5) concentrations but were significantly different in total CYP concentrations and NADPH-P450 reductase activity (P < 0.05). Significant ethnic differences in intrinsic clearance were observed for CYP1A2, CYP2C9, CYP2C19 and CYP2E1; the median values of the Chinese group were 54, 58, 26, and 35% of the corresponding values of the Caucasian group, respectively. These differences were associated with differences in Michaelis constant or maximum velocity. Despite negligible difference in intrinsic clearance, the Michaelis constant of CYP2B6 appeared to have a significant ethnic difference. No ethnic difference was observed for CYP2A6, CYP2C8, CYP2D6 and CYP3A.
These data extend our knowledge on the ethnic differences in CYP enzymes and will have implications for drug discovery and drug therapy for patients from different ethnic origins.
药物反应变异性的最常见原因包括药物代谢的差异,尤其是当涉及到肝细胞色素 P450(CYP)酶时。本研究旨在评估中西方人群肝微粒体(HLM)中 CYP 活性的差异。
利用酶动力学比较 30 个中国肝微粒体样本和 30 个白种人肝微粒体样本中 CYP 酶的代谢能力。利用酶动力学比较 30 个中国肝微粒体样本和 30 个白种人肝微粒体样本中 CYP 酶的代谢能力。以苯乙酮 O-去乙基化、香豆素 7-羟化、丁丙诺啡羟化、阿莫地喹 N-去乙基化、双氯芬酸 4'-羟化(S)-美芬妥因 4'-羟化、右美沙芬 O-去甲基化、氯唑沙宗 6-羟化和咪达唑仑 1'-羟化/睾酮 6β-羟化分别作为 CYP1A2、CYP2A6、CYP2B6、CYP2C8、CYP2C9、CYP2C19、CYP2D6、CYP2E1 和 CYP3A 的活性探针。采用曼-惠特尼 U 检验评估差异。
两组样本在细胞色素 b5 浓度上无显著差异,但在总 CYP 浓度和 NADPH-P450 还原酶活性上有显著差异(P<0.05)。CYP1A2、CYP2C9、CYP2C19 和 CYP2E1 的内在清除率存在显著的种族差异;中国组的中位数分别为白种人组相应值的 54%、58%、26%和 35%。这些差异与米氏常数或最大速度有关。尽管内在清除率差异很小,但 CYP2B6 的米氏常数似乎存在显著的种族差异。CYP2A6、CYP2C8、CYP2D6 和 CYP3A 则没有种族差异。
这些数据扩展了我们对 CYP 酶种族差异的认识,将对不同种族来源的患者的药物发现和药物治疗产生影响。